Becton, Dickinson and Company $BDX Shares Sold by Nuance Investments LLC

Nuance Investments LLC lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 125,213 shares of the medical instruments supplier’s stock after selling 41,322 shares during the quarter. Becton, Dickinson and Company makes up about 2.7% of Nuance Investments LLC’s portfolio, making the stock its 13th biggest holding. Nuance Investments LLC’s holdings in Becton, Dickinson and Company were worth $24,300,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Steph & Co. boosted its position in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 65 shares during the last quarter. WPG Advisers LLC boosted its position in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 61 shares during the last quarter. Accredited Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 70 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.2%

NYSE BDX opened at $151.33 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock has a market capitalization of $41.70 billion, a P/E ratio of 38.31, a PEG ratio of 10.59 and a beta of 0.22. The firm’s 50-day moving average is $150.72 and its two-hundred day moving average is $175.54. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,913 shares of company stock worth $426,806 in the last 90 days. 0.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

BDX has been the topic of several recent research reports. Jefferies Financial Group lowered their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Zacks Research raised shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. TD Cowen decreased their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research report on Monday, May 4th. Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $183.64.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.